Search results for: gout

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP | November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

3 AC&R Study Summaries: Fractures in Patients with SSc, Clinical Response in JIA, & TV & the Public Perception of Gout

Arthritis Care & Research | August 13, 2023

Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…

Pegloticase Plus Methotrexate Effective for Uncontrolled Gout

Glen Rodman | August 8, 2023

The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.

Treat to Target Lowers the Risk of Fracture in Patients with Gout

Arthritis & Rheumatology | July 26, 2023

Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.

What Is Pseudogout?

From the College | June 30, 2023

Tigulixostat Promising for Patients with Gout & Hyperuricemia

Arthritis & Rheumatology | June 28, 2023

In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.

Gout Prophylaxis: How Long Should It Continue?

From the College | March 30, 2023

3 AC&R Study Summaries: Treat to Target in Gout, Response to Biologics in Patients with JIA, & Rehabilitation Dose in Adults with RA

Arthritis Care & Research | February 14, 2023

Treat to Target in Gout Monitoring & achievement of target serum urate levels By Jing Li & Gabriela Schmajuk, MD, MS Why was this study done? The ACR’s 2020 guideline for the management of gout recommends using a treat-to-target (T2T) approach to lower serum urate (SU). Using the ACR’s RISE registry, we examined the use…

Gout & Excess Risk of Severe SARS-CoV-2 Infection

Arthritis & Rheumatology | January 3, 2023

In this large, population-based study, Xie et al. found that the risks of SARS-CoV-2 infection, 30-day hospitalization and 30-day death were higher among individuals with gout than individuals without gout in the general population, irrespective of COVID-19 vaccination status.

Considering Benzbromarone as First-Line Therapy for Gout

Arthritis & Rheumatology | December 1, 2022

In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.